



Divi's Laboratories Limited

Regd. Office: 1-72/23(P)/DIVIS/303, Divi Towers, Cyber Hills, Gachibowli, Hyderabad - 500032. CIN: L24110TG1990PLC011854
Phone: 040-23786300 Fax: 040-23786460 email: mail@divislabs.com website: www.divislabs.com

EXTRACT OF STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th SEPTEMBER, 2017

(₹ in Lakhs)

Particulars	STANDALONE					
	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
	30.09.2017 (Unaudited)	30.06.2017 (Unaudited)	30.09.2016 (Unaudited)	30.09.2017 (Unaudited)	30.09.2016 (Unaudited)	31.03.2017 (Audited)
Total Income from operations	92379	85088	102570	177467	205920	414175
Net Profit / (Loss) for the period (before Tax and Exceptional items)	27611	24170	28034	51781	66990	138823
Net Profit / (Loss) for the period before tax (after Exceptional items)	27611	24170	28034	51781	66990	138823
Net Profit / (Loss) for the period after tax (after Exceptional items)	20678	17654	22385	38332	52566	105327
Total Comprehensive Income for the period [comprising Profit/ (Loss) for the period (after tax)] and Other Comprehensive Income (after tax)]	20640	17618	22320	38258	52436	105187
Equity Share Capital	5309	5309	5309	5309	5309	5309
Reserves (excluding Revaluation Reserve as shown in the Audited Balance Sheet of the previous year)						535582
Earnings Per Share (of ₹ 2/- each) (not annualised) Basic & Diluted (₹)	7.79	6.65	8.43	14.44	19.80	39.68

Notes:

- The above is an extract of the detailed format of Un-audited Financial Results for the quarter and half year ended 30th September 2017 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Other Disclosure Requirements) Regulations, 2015. The full format of the Un-audited Financial Results for the quarter and half year ended 30th September, 2017 are available on the Websites of Stock Exchanges (www.bseindia.com and www.nseindia.com) and also available on the Company's website www.divislabs.com.
- The format for un-audited quarterly results as prescribed in SEBI's Circular No.CIR/CFD/CMD/15/2015 dated 30th November, 2015 has been modified to comply with requirements of SEBI's Circular dated 5th July, 2016, Ind AS Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with Ind AS.
- The company's Unit-II at Visakhapatnam, Andhra Pradesh was inspected by HPRA (Ireland) and JAZMP (Slovenia) from 31st July, 2017 to 4th August, 2017 and the inspection concluded successfully with no critical observations.
- The company's Unit-II has also been inspected by the US-FDA from 11th September 2017 to 19th September 2017. This inspection was for full cGMP and verification of all Corrective Actions proposed against the previous Inspection observations of Nov-Dec, 2016. All the previous observations have been confirmed as completed and resolved. On completion of the current inspection, the Investigators of US-FDA have issued a Form-483 with 6 observations and the company filed its response to the same within the stipulated time.
- Revenue for the corresponding previous quarters ended 30th June, 2017 and 30th September, 2016, the half-year ended 30th September, 2016 and the year ended 31st March, 2017 were reported inclusive of Excise Duty. The Government of India has implemented Goods and Services Tax (GST) effective 1st July, 2017 replacing excise duty, service tax and other indirect taxes. Accordingly, as per Ind AS 18, Revenue for the quarter ended 30th September, 2017 is reported net of GST. Had the previously reported revenue been shown net of excise duty, comparative revenue of the company would have been as under:

(₹ in Lakhs)

	Quarter ended			Half Year ended		Year ended
	30.09.2017	30.06.2017	30.09.2016	30.09.2017	30.09.2016	31.03.2017
Revenue from operations (net of excise duty)	88752	81263	99418	170015	200226	402386

- As approved by the Members of the company at the 27th Annual General Meeting held on 25th September, 2017, the company has disbursed on 10th October, 2017 a dividend of ₹10 per equity share of ₹2 each for the year ended 31st March, 2017, aggregating to ₹26547 lakhs.

for Divi's Laboratories Limited

Dr. Murali K. Divi
Chairman & Managing Director

Place : Hyderabad
Date : 31.10.2017

Size: 16x16 Cms